Synonyms: compound 32 [WO2019226977A1] [1]
Compound class:
Synthetic organic
Comment: Polvitolimod is classified as a toll-like receptor agonist in WHO proposed INN list 126 (January 2022). It was included in the 'COVID' section of that list. Patent mining suggests that polvitolimod is a TLR7 agonist prodrug, that was developed by Primmune Therapeutics as a potential treatment of cancer and infectious disease. In patent WO2019226977 polvitolimod's chemical structure matches that of Compound 32 [1]. Assessment of Primmune Therapeutics' pipeline indicates that polvitolimod is likely to be their clinical candidate PRTX007. If this is the correct name-to-structure association the active drug (PRX034) is likely to be compound 27 as claimed in the patent.
|
|
References |
1. Webber SE, Appleman JR. (2019)
Tlr7 agonists. Patent number: WO2019226977A1. Assignee: Primmune Therapeutics, Inc.. Priority date: 25/05/2018. Publication date: 28/11/2019. |